TheEdgeResearch
Home / Stocks / FTH

Faeth Therapeutics, Inc. (FTH)

NASDAQ Healthcare Biotechnology
$7.88 ▼ -9.32%
Market Cap
$203.1M
Sector
Healthcare
Industry
Biotechnology
Beta
-0.30
52-Wk Range
7.45-42.143
CEO
Anand Parikh
Country
US
Currency
USD

Faeth Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Rockville, MD, US. The stock last traded at $7.88, down 9.32% on the session, giving a market capitalisation of $203.1M. On trailing twelve-month figures it carries a trailing P/E of -0.06, a net margin of 0.0%. Its beta of -0.30 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.06
Price / Sales
0.00
Price / Book
1.21
EV / EBITDA
-0.89
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
16.12
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
29
IPO date
2021-02-04
Headquarters
Rockville, MD, US
About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]

Comparable companies

Faeth Therapeutics, Inc. is most often compared with the following Healthcare names:

BOLDJANXKURAKZIANUVBPBYIPRLDRLAYTNGXVSTM
More research on FTH
FTH technical analysis FTH TheEdge Score Compare against peers
Open full interactive analysis & DCF →